{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:51:45Z","timestamp":1762102305673},"reference-count":17,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2018.6988","type":"journal-article","created":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T08:27:19Z","timestamp":1542616039000},"source":"Crossref","is-referenced-by-count":7,"title":["Cutaneous leukocytoclastic vasculitis associated with erlotinib treatment: A case report and review of the literature"],"prefix":"10.3892","author":[{"given":"Gyula","family":"Fekete","sequence":"first","affiliation":[{"name":"Dermatology Clinic, University of Medicine and Pharmacy, 540530 T\ufffdrgu Mure\u015f, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\ufffdszl\ufffd","family":"Fekete","sequence":"additional","affiliation":[{"name":"CMI Dermamed, 540530 T\ufffdrgu Mure\u015f, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2018,11,19]]},"reference":[{"key":"key20200713115903_b1-etm-0-0-6988","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3109\/15569527.2013.780179","article-title":"Cutaneous leukocytoclastic vasculitis due to erlotinib: Just an adverse event or also a putative marker of drug efficacy?","volume":"32","author":"Brandi","year":"2013","journal-title":"Cutan Ocul Toxicol"},{"key":"key20200713115903_b2-etm-0-0-6988","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1007\/s00228-013-1532-6","article-title":"French Network of Regional Pharmacovigilance Centers: Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors","volume":"69","author":"Faye","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"key20200713115903_b3-etm-0-0-6988","doi-asserted-by":"publisher","first-page":"238","DOI":"10.4103\/0019-5154.177793","article-title":"Cutaneous leukocytoclastic vasculitis associated with erlotinib","volume":"61","author":"Sawada","year":"2016","journal-title":"Indian J Dermatol"},{"key":"key20200713115903_b4-etm-0-0-6988","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1093\/annonc\/mdm420","article-title":"Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib","volume":"18","author":"Boeck","year":"2007","journal-title":"Ann Oncol"},{"key":"key20200713115903_b5-etm-0-0-6988","first-page":"65","article-title":"Erlotinib-induced rosacea-like dermatitis","volume":"24","author":"Rezakovi\u0107","year":"2016","journal-title":"Acta Dermatovenerol Croat"},{"key":"key20200713115903_b6-etm-0-0-6988","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5070\/D3202021539","article-title":"Erlotinib induced target-like purpura","volume":"20","author":"Rungtrakulchai","year":"2014","journal-title":"Dermatol Online J"},{"key":"key20200713115903_b7-etm-0-0-6988","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1080\/15569527.2017.1355316","article-title":"Common and uncommon adverse cutaneous reactions to erlotinib: A study of 20 Chinese patients with cancer","volume":"37","author":"Zhu","year":"2018","journal-title":"Cutan Ocul Toxicol"},{"key":"key20200713115903_b8-etm-0-0-6988","first-page":"E121","article-title":"A case of necrotizing vasculitis with panniculitis, during sorafenib treatment for hepatocellular carcinoma, appeared in disease progression","volume":"5","author":"Panebianco","year":"2014","journal-title":"J Gastrointest Oncol"},{"key":"key20200713115903_b9-etm-0-0-6988","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1159\/000331419","article-title":"Leukocytoclastic vasculitis after long-term treatment with sunitinib: A case report","volume":"4","author":"Karadimou","year":"2011","journal-title":"Case Rep Oncol"},{"key":"key20200713115903_b10-etm-0-0-6988","first-page":"663","article-title":"A case of cutaneous vasculitis caused by erlotinib treatment and a review of literature","volume":"49","author":"Takahashi","year":"2011","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"key":"key20200713115903_b11-etm-0-0-6988","first-page":"3890","article-title":"Erlotinib induced vasculitis","volume":"3","author":"Hakeem","year":"2015","journal-title":"JMSCR"},{"key":"key20200713115903_b12-etm-0-0-6988","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.3892\/ol.2012.647","article-title":"Successful rechallenge with reduced dose of erlotinib in a patient with lung adenocarcinoma who developed erlotinib-associated leukocytoclastic vasculitis: A case report","volume":"3","author":"Su","year":"2012","journal-title":"Oncol Lett"},{"key":"key20200713115903_b13-etm-0-0-6988","first-page":"81","article-title":"Henoch-Sch\u00f6nlein purpura induced by erlotinib (Tarceva): A case report","volume":"48","author":"Yuba","year":"2010","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"key":"key20200713115903_b14-etm-0-0-6988","first-page":"943","article-title":"A spectrum of cutaneous toxicities from erlotinib may be a robust clinical marker for non-small-cell lung therapy: A case report and literature review","volume":"8","author":"Jin","year":"2015","journal-title":"Onco Targets Ther"},{"key":"key20200713115903_b15-etm-0-0-6988","doi-asserted-by":"publisher","first-page":"e55128","DOI":"10.1371\/journal.pone.0055128","article-title":"Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: A systematic review and meta-analysis","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"key20200713115903_b16-etm-0-0-6988","first-page":"785","article-title":"Drug-induced Rowell syndrome, a rare and difficult to manage disease: A case report","volume":"15","author":"Br\u0103ni\u0219teanu","year":"2018","journal-title":"Exp Ther Med"},{"key":"key20200713115903_b17-etm-0-0-6988","first-page":"12321","article-title":"Molecular characterization of virulence and resistance features in Staphylococcus aureus clinical strains isolated from cutaneous lesions in patients with drug adverse reactions","volume":"22","author":"Gheorghe","year":"2017","journal-title":"Rom Biotechnol Lett"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T07:36:32Z","timestamp":1694072192000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2018.6988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,19]]},"references-count":17,"URL":"https:\/\/doi.org\/10.3892\/etm.2018.6988","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,19]]}}}